Showing 6,049 results

Filters Content type: News, Editors' picks, About HIV Topic: HIV treatment

Treatment is recommended for all people living with HIV. It involves taking a combination of antiretroviral drugs. This stops the virus from replicating and allows the immune system to strengthen and fight infections.

Treatment outcomes & life expectancy

HIV-positive New Yorkers are living longer but still dying from underlying infection, not just from old age

Editor's pick
EurekAlert
29 August 2019
Side effects

Those Truvada Lawsuit Ads You See Everywhere May Hinder Public Health Efforts

Editor's pick
TheBody
28 August 2019
Cardiovascular disease

Combining statins and physical exercise has big benefits for people with HIV and high lipids

News
28 August 2019
Changing treatment

‘Alarming’ rates of second-line HIV treatment failure in sub-Saharan Africa

Editor's pick
Avert
22 August 2019
HIV treatment for children & young people

Dolutegravir for younger children: results from the ODYSSEY trial

Editor's pick
HIV i-Base
22 August 2019
New & experimental HIV treatments

ViiV Healthcare reports positive phase III study results of investigational, long-acting, injectable HIV-treatment regimen administered every two months

Editor's pick
GSK press release
22 August 2019
Mental & emotional health problems

Massive decline in suicides of HIV-positive people since the introduction of combination therapy, but rate remains high

News
21 August 2019
Bad science & bogus treatments

Catfished by a Fake AIDS Conference!

Editor's pick
TheBody
20 August 2019
Adherence

Directly observed therapy can be a useful tool in caring for people with HIV treatment failure

News
13 August 2019
Kidney problems

Change in Kidney Function After TDF-to-TAF Switch: Who Benefits Most?

Editor's pick
NATAP
10 August 2019
Injectable & long-acting HIV treatment

DURECT and Gilead Enter into License Agreement for Long-Acting Injectable HIV Investigational Product

Editor's pick
DURECT press release
6 August 2019
People with limited treatment options

Dramatic decline in proportion of people with extensive resistance to anti-HIV medications

News
6 August 2019
Resistance

Alarming surge in drug-resistant HIV uncovered

Editor's pick
Nature
3 August 2019
Changing treatment

High efficacy from switching to bictegravir/F/TAF in virally suppressed participants – including analyses by baseline drug resistance

Editor's pick
i-Base
2 August 2019
People with limited treatment options

Clinical and Economic Effects of Ibalizumab for Multidrug-Resistant HIV

Editor's pick
Infectious Disease Advisor
2 August 2019
Injectable & long-acting HIV treatment

ViiV Healthcare submits regulatory application to EMA for the first monthly, injectable treatment for HIV

Editor's pick
ViiV press release
30 July 2019
People with limited treatment options

EMA panel recommends ibalizumab for multidrug-resistant HIV-1

Editor's pick
Medscape (requires free registration)
30 July 2019
HIV treatment for children & young people

Without frequent viral load monitoring dolutegravir-based regimens not the best choice for African youth on failing ART

News
30 July 2019
Treatment for women

What’s in a pill? Promise, uncertainty, rands, lives & loves … but rights? What the next big thing in HIV treatment for SA shows us

Editor's pick
Bhekisisa
29 July 2019
Changing treatment

Biktarvy Suppresses HIV Well in Women and Those With Drug Resistance

Editor's pick
POZ
29 July 2019
Transgender people

HIV outcomes for transgender women improved by addressing social and structural issues

News
29 July 2019
People with limited treatment options

Fostemsavir salvage therapy continues to look good at 96 weeks

News
29 July 2019
Treatment simplification strategies

Dolutegravir dual therapy works well for both first line and maintenance treatment

News
29 July 2019
The search for a cure

First trial results of new immune-modulating drugs presented in Mexico City

News
26 July 2019